Crinetics Pharmaceuticals, INC Form 4 insider transactions

Richard Scott Struthers, President & CEO and a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on August 7, 2026.

Director Rogerio Vivaldi Coelho has sold 3,000 shares of Crinetics Pharmaceuticals, Inc. common stock for $40 per share, executed under a Rule 10b5-1 trading plan.

Director Stephanie Okey of Crinetics Pharmaceuticals, Inc. (CRNX) reported the sale of common stock totaling 6,890 shares, executed under a Rule 10b5-1 trading plan.

Richard Scott Struthers, Director and President & CEO of Crinetics Pharmaceuticals, Inc., reported significant changes in beneficial ownership of common stock on May 29, 2026.

Jeff E. Knight, Chief Development & Operating Officer of Crinetics Pharmaceuticals, Inc., reported the sale of 85,163 shares of common stock on April 8, 2026, executed under a Rule 10b5-1 trading plan.

Crinetics Pharmaceuticals Director Rogerio Vivaldi Coelho sold 5,000 shares of common stock for approximately $180,740 through a pre-arranged Rule 10b5-1 trading plan.

Crinetics Pharmaceuticals Director Stephanie Okey sold 3,000 shares of common stock for $39.67 each, executed under a pre-arranged 10b5-1 trading plan.

Crinetics Pharmaceuticals' CFO, Tobin Schilke, sold 6,713 shares of common stock at an average price of $39.67 to cover tax withholding obligations related to RSU vesting.

Crinetics Pharmaceuticals CEO Richard Scott Struthers acquired 62,000 restricted stock units and 228,000 stock options, signaling increased long-term alignment with shareholder interests.

Crinetics Pharmaceuticals' CFO, Tobin Schilke, reported the acquisition of 32,000 restricted stock units and 50,000 stock options.

Crinetics Pharmaceuticals' Chief Operating Officer, Jeff Knight, acquired 34,000 restricted stock units and 55,000 stock options.

Crinetics Pharmaceuticals' Chief Scientific Officer, Stephen F. Betz, was granted 30,000 restricted stock units and 47,000 stock options as part of his compensation.

Crinetics Pharmaceuticals' Chief Commercial Officer, Isabel Kalofonos, received 34,000 restricted stock units and 55,000 stock options as part of her compensation.

Crinetics Pharmaceuticals' Chief Commercial Officer, Isabel Kalofonos, exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Crinetics Pharmaceuticals' Chief Scientific Officer, Stephen F. Betz, exercised options to acquire 18,000 shares of common stock at $1.91 per share.

Crinetics Pharmaceuticals' President and CEO, Richard Scott Struthers, exercised stock options for 44,742 shares of common stock.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and subsequently sold 5,000 shares of common stock for $41.81 per share.

Crinetics Pharmaceuticals' President and CEO, Richard Scott Struthers, sold 4,000 shares of common stock for $180,000 through a pre-arranged Rule 10b5-1 trading plan.

Crinetics Pharmaceuticals Director Matthew K. Fust exercised stock options and subsequently sold a portion of his common stock holdings for a significant profit, as per a pre-arranged trading plan.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and sold 5,000 shares of common stock under a pre-arranged trading plan.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, sold 30,000 shares of common stock for $30.43 per share after exercising options.

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, sold 6,492 shares of common stock for $29.18 per share.

Crinetics Pharmaceuticals' Chief Scientific Officer, Stephen F. Betz, reported the exercise of stock options and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan.

Crinetics Pharmaceuticals, Inc. Director Stephanie Okey was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation, aligning her interests with shareholders.

Crinetics Pharmaceuticals, Inc. Director Caren Deardorf was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation, increasing her beneficial ownership.

Crinetics Pharmaceuticals, Inc. Director Rogerio Vivaldi Coelho was granted 6,900 restricted stock units and 10,350 stock options as part of his compensation, aligning his interests with shareholders.

Matthew K. Fust, a Director at Crinetics Pharmaceuticals, Inc. (CRNX), reported the acquisition of 6,900 restricted stock units and 10,350 stock options as part of his compensation.

Camille L. Bedrosian, a Director at Crinetics Pharmaceuticals, Inc., was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation.